Kyung Bo Kim
Cited by
Cited by
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
KM Sakamoto, KB Kim, A Kumagai, F Mercurio, CM Crews, RJ Deshaies
Proceedings of the National Academy of Sciences 98 (15), 8554-8559, 2001
The ubiquitin‐proteasome pathway and proteasome inhibitors
J Myung, KB Kim, CM Crews
Medicinal research reviews 21 (4), 245-273, 2001
Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha', beta'-epoxyketone proteasome inhibitors
M Groll, KB Kim, N Kairies, R Huber, CM Crews
Journal of the American Chemical Society 122 (6), 1237-1238, 2000
Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation
KM Sakamoto, KB Kim, R Verma, A Ransick, B Stein, CM Crews, ...
Molecular & Cellular Proteomics 2 (12), 1350-1358, 2003
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
IR Garrett, D Chen, G Gutierrez, M Zhao, A Escobedo, G Rossini, ...
Journal of Clinical Investigation 111 (11), 1771-1782, 2003
The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin
P Bargagna-Mohan, A Hamza, Y Kim, Y Khuan Abby Ho, N Mor-Vaknin, ...
Chemistry & biology 14 (6), 623-634, 2007
Total synthesis of the-potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology
N Sin, KB Kim, M Elofsson, L Meng, H Auth, BHB Kwok, CM Crews
Bioorganic & medicinal chemistry letters 9 (15), 2283-2288, 1999
cGAS drives noncanonical-inflammasome activation in age-related macular degeneration
N Kerur, S Fukuda, D Banerjee, Y Kim, D Fu, I Apicella, A Varshney, ...
Nature medicine 24 (1), 50-61, 2018
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
A Rodriguez-Gonzalez, K Cyrus, M Salcius, K Kim, CM Crews, ...
Oncogene 27 (57), 7201-7211, 2008
Impact of linker length on the activity of PROTACs
M Wehenkel, EY Choi, HJ Han, H Lee, H Swanson, KB Kim
Molecular BioSystems 7 (2), 359-364, 2011
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes
K BoŠKim
Natural product reports 30 (5), 600-604, 2013
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency
KB Kim, J Myung, N Sin, CM Crews
Bioorganic & medicinal chemistry letters 9 (23), 3335-3340, 1999
Lack of proteasome active site allostery as revealed by subunit-specific inhibitors
J Myung, KB Kim, K Lindsten, NP Dantuma, CM Crews
Molecular cell 7 (2), 411-420, 2001
LMP2-specific inhibitors: chemical genetic tools for proteasome biology
YKA Ho, P Bargagna-Mohan, M Wehenkel, R Mohan, KB Kim
Chemistry & biology 14 (4), 419-430, 2007
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up-or down-regulate antigen presentation at nontoxic doses
K Schwarz, R de Giuli, G Schmidtke, S Kostka, M van den Broek, KB Kim, ...
The Journal of Immunology 164 (12), 6147-6157, 2000
Next-generation proteasome inhibitors for cancer therapy
JE Park, Z Miller, Y Jun, W Lee, KB Kim
Translational Research 198, 1-16, 2018
Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes
G de Bruin, EM Huber, BT Xin, EJ van Rooden, K Al-Ayed, KB Kim, ...
Journal of medicinal chemistry 57 (14), 6197-6209, 2014
Inhibitors of the immunoproteasome: current status and future directions
Z Miller, L Ao, K Bo Kim, W Lee
Current pharmaceutical design 19 (22), 4140-4151, 2013
Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention
D Puppala, H Lee, KB Kim, HI Swanson
Molecular pharmacology 73 (4), 1064-1071, 2008
Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor‐Targeting PROTACs
K Cyrus, M Wehenkel, EY Choi, H Lee, H Swanson, KB Kim
ChemMedChem 5 (7), 979-985, 2010
The system can't perform the operation now. Try again later.
Articles 1–20